Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone.
bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab.
bioMérieux (Euronext: BIM), a global leader in the field of in vitro diagnostics, today released its interim financial report for the first six months of 2008.
A world leader in the field of in vitro diagnostics, bioMérieux has appointed Steve Harbin as Corporate Vice President, Quality Management Systems, Health, Safety and Environment and Internal Control, effective July 15, 2008.
pharma_media1_thumb15.jpg bioMérieux, a world leader in in vitro diagnostics, launches sterility media bottles in a new format, the Clean Room Range, for ultimate quality and ease of use in final product testing of sterile pharmaceutical compounds.
VIDAS® offers the only fully automated test for C. difficile Toxin A&B.
Seventh Annual Symposium to cover food-borne outbreaks including Salmonella and E. coli O157:H7.
VIDAS® UP Recombinant Phage Technology Delivers Unprecedented Level
Survey shows hospital physicians, pulmonary and critical care clinicians, and researchers also concerned about overuse of antibiotics.
bioMérieux providing high medical-value tests such as Procalcitonin, Cardiovascular Critical Care Range and CDA+B.
